title: Nitric Oxide does not mediate Atrogin-1/MAFbx upregulation by inflammatory mediators.
abstract: Accelerated proteolysis through the ubiquitin-proteasome system has been recognized as a major contributor to muscle wasting, a serious complication frequently associated with a number of inflammatory disorders. Muscle expression of atrogin-1/MAFbx, a rate-limiting ubiquitin ligase for muscle wasting, is upregulated in various inflammatory conditions, and is considered a therapeutic target for muscle wasting. As one of the free radicals whose production is elevated in inflammatory conditions, nitric oxide (NO) is implicated in the pathogenesis of muscle wasting. To understand how inflammatory mediators upregulate atrogin-1/MAFbx expression, we tested the hypothesis that NO mediates the upregulation of atrogin-1/MAFbx expression. C2C12 myotubes were incubated with a cocktail comprised of TNF-α, interferon γ and lipopolysaccharide (LPS), which stimulated NO production and atrogin-1/MAFbx expression. Pre-incubation of the myotubes with nitric oxide synthase (NOS) inhibitor L-NAME or S-ethylisothiourea (SETU) blocked the stimulation of NO production by the cocktail. However, the stimulation of atrogin-1/MAFbx expression was not disrupted. Intraperitoneal administration of LPS to mice resulted in elevated atrogin-1/MAFbx expression in gastrocnemius muscle. But, pretreatment of the mice with L-NAME did not alter LPS stimulation of atrogin-1/MAFbx expression. Therefore, NO does not mediate upregulation of atrogin-1/MAFb expression by inflammatory mediators.
authors: Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
authors: Bingwen
authors: B
authors: Jin
authors: Yi-Ping
authors: YP
authors: Li
references: Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14440-5
references: 11717410
references: EMBO J. 1996 Apr 15;15(8):1753-65
references: 8617220
references: J Clin Invest. 2004 Aug;114(3):370-8
references: 15286803
references: Cell. 2004 Oct 15;119(2):285-98
references: 15479644
references: Am J Physiol Regul Integr Comp Physiol. 2000 Oct;279(4):R1165-70
references: 11003979
references: Anal Biochem. 1982 Oct;126(1):131-8
references: 7181105
references: Cancer Lett. 2002 Jun 6;180(1):69-74
references: 11911972
references: Biochem Biophys Res Commun. 1995 Jan 17;206(2):533-40
references: 7530002
references: Int J Biochem Cell Biol. 2005 Oct;37(10):2036-46
references: 16105746
references: FASEB J. 1998 Jul;12(10):871-80
references: 9657527
references: Cell. 2004 Apr 30;117(3):399-412
references: 15109499
references: Annu Rev Biochem. 1998;67:425-79
references: 9759494
references: Biol Neonate. 2003;84(4):319-24
references: 14593243
references: Muscle Nerve. 2006 Feb;33(2):155-65
references: 16228971
references: Am J Physiol Cell Physiol. 2003 Oct;285(4):C806-12
references: 12773310
references: JPEN J Parenter Enteral Nutr. 1998 May-Jun;22(3):156-66
references: 9586794
references: FEBS Lett. 2003 Jun 5;544(1-3):214-7
references: 12782319
references: FASEB J. 2004 Jan;18(1):39-51
references: 14718385
references: J Clin Invest. 2007 Sep;117(9):2468-76
references: 17786240
references: Curr Opin Clin Nutr Metab Care. 2001 May;4(3):183-90
references: 11517350
references: Muscle Nerve. 2007 Apr;35(4):411-29
references: 17266144
references: Mol Cell. 2004 May 7;14(3):395-403
references: 15125842
references: Am J Physiol. 1995 Mar;268(3 Pt 1):L509-18
references: 7534998
references: J Natl Cancer Inst. 1997 Dec 3;89(23):1763-73
references: 9392617
references: J Anim Sci. 2008 Apr;86(14 Suppl):E84-93
references: 18192560
references: Biochem Soc Trans. 1995 Nov;23(4):1019-25
references: 8654673
references: J Cell Biochem. 2007 Mar 1;100(4):960-9
references: 17131360
references: Science. 2001 Nov 23;294(5547):1704-8
references: 11679633
references: FASEB J. 2005 Mar;19(3):362-70
references: 15746179